Alterity Therapeutics Secures FDA Agreement on Proposed ATH434 Phase 3 Trial Design

The FDA agreed with the design of Alterity Therapeutics’ proposed pivotal Phase 3 trial of ATH434 for multiple system atrophy. Approval is not guaranteed; the regulator indicated one pivotal trial supported by confirmatory evidence.